Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Roy Winston Sells 476 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating) insider Roy Winston sold 476 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $55.70, for a total transaction of $26,513.20. Following the completion of the transaction, the insider now directly owns 44,992 shares in the company, valued at approximately $2,506,054.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Roy Winston also recently made the following trade(s):

  • On Monday, June 6th, Roy Winston sold 17,546 shares of Pacira BioSciences stock. The stock was sold at an average price of $61.39, for a total transaction of $1,077,148.94.

Pacira BioSciences Trading Up 2.3 %

Pacira BioSciences stock opened at $58.89 on Friday. The stock has a market cap of $2.68 billion, a P/E ratio of 71.82 and a beta of 0.85. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.95 and a quick ratio of 1.85. Pacira BioSciences, Inc. has a 1 year low of $45.05 and a 1 year high of $82.16. The firm’s 50 day moving average price is $57.04 and its 200-day moving average price is $64.64.

Pacira BioSciences (NASDAQ:PCRXGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.34). The company had revenue of $169.41 million for the quarter, compared to the consensus estimate of $169.27 million. Pacira BioSciences had a net margin of 6.39% and a return on equity of 13.13%. The company’s quarterly revenue was up 24.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS. On average, equities analysts predict that Pacira BioSciences, Inc. will post 2.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Rafferty Asset Management LLC increased its position in Pacira BioSciences by 4.4% in the fourth quarter. Rafferty Asset Management LLC now owns 7,454 shares of the company’s stock worth $449,000 after purchasing an additional 312 shares during the last quarter. Rice Hall James & Associates LLC increased its position in Pacira BioSciences by 25.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 420,205 shares of the company’s stock worth $25,284,000 after purchasing an additional 86,256 shares during the last quarter. Rhumbline Advisers increased its position in Pacira BioSciences by 1.0% in the fourth quarter. Rhumbline Advisers now owns 110,427 shares of the company’s stock worth $6,644,000 after purchasing an additional 1,130 shares during the last quarter. Swiss National Bank increased its position in Pacira BioSciences by 0.6% in the fourth quarter. Swiss National Bank now owns 97,800 shares of the company’s stock worth $5,885,000 after purchasing an additional 600 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in Pacira BioSciences in the first quarter worth $19,296,000.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Needham & Company LLC lowered their price target on shares of Pacira BioSciences from $84.00 to $76.00 and set a “buy” rating on the stock in a report on Wednesday, June 15th. Piper Sandler lowered their price target on shares of Pacira BioSciences from $84.00 to $80.00 and set an “overweight” rating on the stock in a report on Thursday, July 21st. Finally, TheStreet raised shares of Pacira BioSciences from a “c” rating to a “b-” rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $80.75.

About Pacira BioSciences

(Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

Featured Articles

Insider Buying and Selling by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.